News

Published on 24 Mar 2024 on Benzinga

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday - Dada Nexus...

Article preview image

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects Dada Nexus Limited DADA to report quarterly earnings at 9 cents per share on revenue of $432.74 million after the closing bell, according to data from Benzinga Pro. Dada Nexus shares gained 0.9% to $2.33 in after-hours trading.

Read the rest of the article
NASDAQ.SLRX price evolution
NASDAQ.MASI price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In...

Shares of Landos Biopharma, Inc. LABP rose sharply during Monday’s session following acquisition...

Benzinga 25 Mar 2024
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday - Dada Nexus...

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab in...

Benzinga 24 Mar 2024
After Patient Death, Salarius Stops Enrollment In Seclidemstat Trial For Soft Tissue Cancer

Per protocol design, Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is voluntarily pausing new patie...

Benzinga via Yahoo Finance 15 Oct 2022
Salarius Pharmaceuticals attempts to regain Nasdaq compliance with reverse stock split

Houston-based clinical-stage oncology company Salarius Pharmaceuticals Inc. (Nasdaq: SLRX) will...

American City Business Journals 15 Oct 2022
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know

Wall Street expects a year-over-year increase in earnings on lower revenues when Salarius (SLRX) ...

Zacks via Yahoo Finance 11 Feb 2022
Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has agreed to acquire an oral, small molecule targete...

Benzinga via Yahoo Finance 23 Jan 2022
Is Digital Ally, Inc. (DGLY) A Good Stock To Buy?

In this article we will check out the progression of hedge fund sentiment towards Digital Ally, I...

Insider Monkey via Yahoo Finance 3 Dec 2021
Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical On...

Benzinga via Yahoo Finance 28 Oct 2021
Salarius Pharmaceuticals (SLRX) is Developing a Novel LSD1 Inhibitor, Positioning it as a...

Image by the National Cancer Institute on Unsplash The following post was written and/or publishe...

Benzinga via Yahoo Finance 28 Oct 2021
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates

Salarius (SLRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Esti...

Zacks via Yahoo Finance 22 Oct 2021

Copyright Statfolio @ 2024

Social Accounts